NT5E and cancer: 84). More recently, CD73 has gained considerable attention as a target for cancer treatment (Ref. 85). CD73 is upregulated in the majority of human solid tumours in comparison to normal tissues. Among these tumours, we can mention glioblastoma (Ref. 85), thyroid carcinoma (Ref. 86), pancreatic carcinoma (Ref. 87), renal cell carcinoma (Ref. 88) and colorectal carcinoma (Ref. 89). However, in general, in cancers of the genitourinary system, such as endometrial, ovarian, uterine and prostate, a lower expression of CD73 is observed (Ref. 90).